the 12-week results from its Phase 2 study of UBX0101, a p53/MDM2 interaction inhibitor (in 183 patients with moderate-to-severe painful osteoarthritis of the knee) which found no statistically significant difference in pain reduction between the use of UBX0101 and a placebo.